Aspen Pharmacare plunges 30% after flagging contract manufacturing wrangle

Moneyweb

Aspen Pharmacare’s shares plummeted 33% on Wednesday due to a contractual dispute potentially costing R2.77 billion. The Durban-based company warned of a significant financial impact, with around R2 billion in Ebitda and R770 million in impairment. Shares later slightly recovered, trading at around R112.
Read More from source